Poduslo J F, Curran G L
Molecular Neurobiology Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Neuroreport. 2001 Oct 29;12(15):3197-200. doi: 10.1097/00001756-200110290-00011.
Much research is now focused on a potential vaccine for Alzheimer's disease (AD). Current studies involve administering the amyloid beta peptide (Abeta) in Freund's complete adjuvant, which cannot be used in humans. Our studies show that the immune complex of Abeta is taken up by a receptor-mediated process at the blood-brain barrier (BBB). The success of immunization for AD, therefore, may be critically dependent on circulating Abeta levels which are lower in AD patients compared to AD transgenic mice. Moreover, we have found that modifying the antibody with polyamine increases its BBB permeability and may provide a better approach to passive immunization for Alzheimer's disease.
目前许多研究都聚焦于阿尔茨海默病（AD）的潜在疫苗。当前的研究涉及在弗氏完全佐剂中给予β淀粉样肽（Aβ），而这种佐剂不能用于人体。我们的研究表明，Aβ免疫复合物通过血脑屏障（BBB）处受体介导的过程被摄取。因此，AD免疫疗法的成功可能严重依赖于循环Aβ水平，与AD转基因小鼠相比，AD患者的循环Aβ水平较低。此外，我们发现用多胺修饰抗体可增加其血脑屏障通透性，这可能为阿尔茨海默病的被动免疫提供更好的方法。
